Literature DB >> 11528253

Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx.

D Thurnher1, J Kletzmayr, M Formanek, C Quint, C Czerny, M Burian, G Kornek.   

Abstract

OBJECTIVE: A cisplatin-containing regimen followed by radiation therapy is the recommended treatment for patients with advanced nasopharyngeal carcinoma. We report a case of a 58-year-old woman with hemolytic-uremic syndrome (HUS) who received induction chemotherapy for undifferentiated squamous cell carcinoma of the nasopharynx. PATIENTS AND METHODS: During the 2nd course of chemotherapy (consisting of bleomycin, cisplatin and epirubicin), the patient developed hemolytic anemia, thrombocytopenia, and acute renal failure. After HUS had been diagnosed, the patient was transferred to the intensive care unit.
RESULTS: Twice daily therapeutic plasma exchange (TPE) with fresh-frozen plasma, hemodialysis and high-dose cortisone was performed. Two weeks after the start of plasma exchange, thrombocytes and renal function began to normalize. Low-dose cortisone was continued until the patient recovered from hemolytic anemia. Six weeks after the administration of the second course of chemotherapy, the patient had fully recovered from HUS, and radiation therapy was carried out as planned. The patient responded well to treatment, but died 9 months after the diagnosis due to liver metastases.
CONCLUSION: We demonstrated that early TPE with fresh-frozen plasma and high-dose cortisone is a potentially successful treatment modality for the usually fatal, fulminant form of chemotherapy-induced HUS. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528253     DOI: 10.1159/000055365

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.

Authors:  Philipp A Lang; Ortraud Beringer; Jan P Nicolay; Oliver Amon; Daniela S Kempe; Tobias Hermle; Philipp Attanasio; Ahmad Akel; Richard Schäfer; Björn Friedrich; Teut Risler; Matthias Baur; Christoph J Olbricht; Lothar Bernd Zimmerhackl; Peter F Zipfel; Thomas Wieder; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-19       Impact factor: 4.599

2.  Induction of eryptosis by cyclosporine.

Authors:  Olivier M Niemoeller; Ahmad Akel; Philipp A Lang; Philipp Attanasio; Daniela S Kempe; Tobias Hermle; Malgorzata Sobiesiak; Thomas Wieder; Florian Lang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-22       Impact factor: 3.000

3.  Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab.

Authors:  Rodney D Gilbert; Louise K Stanley; Darren J Fowler; Elizabeth M Angus; Steven A Hardy; Timothy H Goodship
Journal:  Clin Kidney J       Date:  2013-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.